CPM may be a rational choice for patients with known BRCA mutations, patients who have received therapeutic chest radiation, and some mastectomy patients.
Todd M. Tuttle, MD
Advertisement
Articles by Todd M. Tuttle, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer
2
Data Readouts to Watch at the 2026 ASCO Annual Meeting
3
Outlining Exercise as a “Biologically Interventional Therapy” for Cancer
4
ArteraAI Pathology Test Launches for Personalizing Prostate Cancer Therapy
5